Edouard Bieth - Biophytis Chief Officer
| BPTSDelisted Stock | USD 7.03 0.00 0.00% |
Executive
Edouard Bieth is Chief Officer of Biophytis
| Phone | 33 1 44 27 23 00 |
| Web | https://www.biophytis.com |
Biophytis Management Efficiency
The company has return on total asset (ROA) of (0.5278) % which means that it has lost $0.5278 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.444) %, meaning that it created substantial loss on money invested by shareholders. Biophytis' management efficiency ratios could be used to measure how well Biophytis manages its routine affairs as well as how well it operates its assets and liabilities.Biophytis currently holds 8.27 M in liabilities with Debt to Equity (D/E) ratio of 3.27, implying the company greatly relies on financing operations through barrowing. Biophytis has a current ratio of 1.34, which is within standard range for the sector. Note, when we think about Biophytis' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Scott Saywell | Coherus BioSciences | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| BethAnne Lang | Akari Therapeutics PLC | N/A | |
| Pierre Kyme | Armata Pharmaceuticals | N/A | |
| Tamara LLM | Spero Therapeutics | 62 | |
| Steven MD | Processa Pharmaceuticals | N/A | |
| Wendy CPA | Akari Therapeutics PLC | 57 | |
| Riccardo Panicucci | NRX Pharmaceuticals | 63 | |
| Jodi Sievers | Coherus BioSciences | N/A | |
| MD III | Akari Therapeutics PLC | 71 | |
| Michael Covarrubias | Rezolute | N/A | |
| Peter Hubbard | Armata Pharmaceuticals | N/A | |
| MS MD | Armata Pharmaceuticals | 49 | |
| PharmD BCOP | Bolt Biotherapeutics | N/A | |
| Erin OBoyle | Rezolute | N/A | |
| Bryan Kadotani | Armata Pharmaceuticals | N/A | |
| Andy Rittenberg | Coherus BioSciences | N/A | |
| Russell MBA | Processa Pharmaceuticals | 65 | |
| Bonne MBA | Inhibrx | 47 | |
| James Stanker | Processa Pharmaceuticals | 66 | |
| Daron Evans | Rezolute | 50 | |
Management Performance
| Return On Equity | -12.44 | |||
| Return On Asset | -0.53 |
Biophytis Leadership Team
Elected by the shareholders, the Biophytis' board of directors comprises two types of representatives: Biophytis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biophytis. The board's role is to monitor Biophytis' management team and ensure that shareholders' interests are well served. Biophytis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biophytis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edouard Bieth, Chief Officer | ||
| Philippe Rousseau, Chief Officer | ||
| Waly Dioh, Chief Officer | ||
| Pierre Dilda, Chief Officer | ||
| Benoit Canolle, Chief Officer | ||
| Stanislas Veillet, Chairman CEO | ||
| Rene Lafont, Scientific Board | ||
| Nicolas Fellmann, Chief Officer | ||
| FFPM MBA, Chief Officer | ||
| Teylan, Financial Controller |
Biophytis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biophytis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.44 | |||
| Return On Asset | -0.53 | |||
| Current Valuation | 9.73 B | |||
| Shares Outstanding | 286.5 K | |||
| Shares Owned By Institutions | 0.04 % | |||
| Number Of Shares Shorted | 368.95 K | |||
| Price To Book | 2.26 X | |||
| EBITDA | (15.09 M) | |||
| Net Income | (17.03 M) | |||
| Cash And Equivalents | 23.93 M |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.
Other Consideration for investing in Biophytis Stock
If you are still planning to invest in Biophytis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biophytis' history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |